Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer.
Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, Ewertz M, Jensen BB, Kamby C, Nordenskjold B, Bergh J. Ejlertsen B, et al. Among authors: mouridsen ht. Eur J Cancer. 2007 Mar;43(5):877-84. doi: 10.1016/j.ejca.2007.01.009. Epub 2007 Feb 16. Eur J Cancer. 2007. PMID: 17306974 Clinical Trial.
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL. Ejlertsen B, et al. Among authors: mouridsen ht. J Clin Oncol. 2006 Nov 1;24(31):4956-62. doi: 10.1200/JCO.2005.05.1235. J Clin Oncol. 2006. PMID: 17075113 Clinical Trial.
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J. Kristensen B, et al. Among authors: mouridsen ht. Acta Oncol. 2008;47(4):740-6. doi: 10.1080/02841860801964988. Acta Oncol. 2008. PMID: 18465343 Clinical Trial.
Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjöström J, Kjaer M; Scandinavian Breast Group Trial (SBG9403. Ejlertsen B, et al. Among authors: mouridsen ht. J Clin Oncol. 2004 Jun 15;22(12):2313-20. doi: 10.1200/JCO.2004.11.503. J Clin Oncol. 2004. PMID: 15197192 Clinical Trial.
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, Mouridsen H, Ejlertsen B, Brünner N. Willemoe GL, et al. Eur J Cancer. 2009 Sep;45(14):2528-36. doi: 10.1016/j.ejca.2009.05.029. Epub 2009 Jun 15. Eur J Cancer. 2009. PMID: 19535243 Clinical Trial.
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study.
Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, Lidbrink E, Lindman H, Mouridsen H, Bjerre K, Andersson M. Rosendahl M, et al. Eur J Cancer. 2009 Dec;45(18):3198-204. doi: 10.1016/j.ejca.2009.09.019. Epub 2009 Oct 7. Eur J Cancer. 2009. PMID: 19818599 Clinical Trial.
334 results